{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:27:15Z","timestamp":1794029235758,"version":"4.8.0"},"reference-count":228,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["24-15-00227"],"award-info":[{"award-number":["24-15-00227"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Autoimmunity arises when the immune system erroneously attacks self-antigens, potentially resulting in organ dysfunction. This review focuses on the proliferation-inducing ligand, APRIL, and its critical role in regulating antibody-producing B cells. We explore the implications of APRIL in autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, and Sj\u00f6gren\u2019s syndrome. Emerging evidence indicates that APRIL may modulate autoimmune pathology and influence B cell survival, particularly through its interactions with receptors like B-cell maturation antigen (BCMA) and transmembrane activator and CAML interactor (TACI). We emphasize the contrasting roles of APRIL and BAFF in autoimmunity, highlighting the conflicting data regarding their contributions to disease progression and activity levels. Furthermore, we evaluate therapeutic strategies aimed at inhibiting APRIL and compare them with existing B-cell-targeted therapies, such as rituximab and belimumab. The potential benefits of specific APRIL antagonism are discussed, especially for patients with antibody-driven autoimmune disorders. This highlights the necessity for further research into APRIL-targeted therapies in clinical practice. Ultimately, this review seeks to provide a comprehensive overview of the current understanding of APRIL\u2019s role in autoimmunity and outline future directions for targeting this ligand in the treatment of autoimmune diseases.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1523392","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T05:32:46Z","timestamp":1754026366000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Exploring the role of APRIL in autoimmunity: implications for therapeutic targeting in systemic lupus erythematosus, rheumatoid arthritis, and Sj\u00f6gren\u2019s syndrome"],"prefix":"10.3389","volume":"16","author":[{"given":"Anastasia V.","family":"Poznyak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena V.","family":"Gerasimova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolay A.","family":"Orekhov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amina Eldarovna","family":"Karimova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Andreevna","family":"Vergun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ksenia Olegovna","family":"Lapshina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasily N.","family":"Sukhorukov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander N.","family":"Orekhov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/pathophysiology29020020","article-title":"The role of exposomes in the pathophysiology of autoimmune diseases II: pathogens","volume":"29","author":"Vojdani","year":"2022","journal-title":"Pathophysiology: Off J Int Soc Pathophysiology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102962","article-title":"Infectious diseases, autoantibodies, and autoimmunity","volume":"137","author":"Johnson","year":"2023","journal-title":"J Autoimmun"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1432985","article-title":"Autoimmunity: the neoantigen hypothesis","volume":"15","author":"Mustelin","year":"2024","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e184046","DOI":"10.1172\/JCI184046","article-title":"Microbial mimics supersize the pathogenic self-response","volume":"134","author":"Capera","year":"2024","journal-title":"J Clin Invest"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-023-07967-5","article-title":"Incorporating the molecular mimicry of environmental antigens into the causality of autoimmune hepatitis","volume":"68","author":"Czaja","year":"2023","journal-title":"Digestive Dis Sci"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2017.01938","article-title":"Morbid sequences suggest molecular mimicry between microbial peptides and self-antigens: A possibility of inciting autoimmunity","volume":"8","author":"Pahari","year":"2017","journal-title":"Front Microbiol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2016.78","article-title":"Germinal centers and autoimmune disease in humans and mice","volume":"94","author":"DeFranco","year":"2016","journal-title":"Immunol Cell Biol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1080\/08916934.2017.1280671","article-title":"Spontaneous germinal centers and autoimmunity","volume":"50","author":"Domeier","year":"2017","journal-title":"Autoimmunity"},{"key":"B9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/imr.12808","article-title":"Clonal redemption and clonal anergy as mechanisms to balance B cell tolerance and immunity","volume":"292","author":"Burnett","year":"2019","journal-title":"Immunol Rev"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-023-00720-1","article-title":"Pathogenesis of autoimmune disease","volume":"19","author":"Pisetsky","year":"2023","journal-title":"Nat Rev Nephrol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1219487","article-title":"Potential therapeutic targets of macrophages in inhibiting immune damage and fibrotic processes in musculoskeletal diseases","volume":"14","author":"Zhu","year":"2023","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/life13041047","article-title":"Sarcoidosis and autoimmune inflammatory syndrome induced by adjuvants","volume":"13","author":"Starshinova","year":"2023","journal-title":"Life (Basel Switzerland)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2011.01076.x","article-title":"Molecular mimicry as an inducing trigger for CNS autoimmune demyelinating disease","volume":"245","author":"Chastain","year":"2012","journal-title":"Immunol Rev"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102459","article-title":"Interaction between food antigens and the immune system: Association with autoimmune disorders","volume":"19","author":"Vojdani","year":"2020","journal-title":"Autoimmun Rev"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.580636","article-title":"Molecular mimicry and uveitis","volume":"11","author":"Wildner","year":"2020","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2016.217","article-title":"Ectopic lymphoid neogenesis in rheumatic autoimmune diseases","volume":"13","author":"Bombardieri","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00603","article-title":"Mechanisms of autoantibody-induced pathology","volume":"8","author":"Ludwig","year":"2017","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-020-00092-2","article-title":"B cell depletion therapies in autoimmune disease: advances and mechanistic insights","volume":"20","author":"Lee","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12216927","article-title":"A PRoliferation-inducing ligand (APRIL) in the pathogenesis of immunoglobulin A nephropathy: A review of the evidence","volume":"12","author":"Mathur","year":"2023","journal-title":"J Clin Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/4516920","article-title":"Advances in the use of stem cells in veterinary medicine: from basic research to clinical practice","volume":"2016","author":"Markoski","year":"2016","journal-title":"Scientifica (Cairo)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9010024","article-title":"B and T cell immunity in tissues and across the ages","volume":"9","author":"Booth","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1900026","article-title":"Ancient BCMA-like genes herald B cell regulation in lampreys","volume":"203","author":"Das","year":"2019","journal-title":"J Immunol (Baltimore Md.: 1950)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/art.42462","article-title":"Povetacicept, an enhanced dual APRIL\/BAFF antagonist that modulates B lymphocytes and pathogenic autoantibodies for the treatment of lupus and other B cell-related autoimmune diseases","volume":"75","author":"Evans","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e2404309121","DOI":"10.1073\/pnas.2404309121","article-title":"Unique and redundant roles of mouse BCMA, TACI, BAFF, APRIL, and IL-6 in supporting antibody-producing cells in different tissues","volume":"121","author":"Eslami","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01821","article-title":"Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy","volume":"9","author":"Cho","year":"2018","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02138","article-title":"Factors affecting early antibody secreting cell maturation into long-lived plasma cells","volume":"10","author":"Nguyen","year":"2019","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2019.1641196","article-title":"B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma","volume":"19","author":"Tai","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.03.016","article-title":"B cell responses: cell interaction dynamics and decisions","volume":"177","author":"Cyster","year":"2019","journal-title":"Cell"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00509","article-title":"Non-canonical NF-\u03baB signaling initiated by BAFF influences B cell biology at multiple junctures","volume":"4","author":"Gardam","year":"2014","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12810","article-title":"BAFF inhibition in SLE-Is tolerance restored","volume":"292","author":"Jackson","year":"2019","journal-title":"Immunol Rev"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.24","article-title":"Altered B cell signalling in autoimmunity","volume":"17","author":"Rawlings","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2021.06.014","article-title":"BAFF signaling in health and disease","volume":"71","author":"Schweighoffer","year":"2021","journal-title":"Curr Opin Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.blre.2016.10.001","article-title":"NF-\u03baB signaling pathway and its potential as a target for therapy in lymphoid neoplasms","volume":"31","author":"Yu","year":"2017","journal-title":"Blood Rev"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1456220","article-title":"Both sides now: evolutionary traits of antigens and B cells in tolerance and activation","volume":"15","author":"Hong","year":"2024","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241411750","article-title":"Atheroprotective aspects of heat shock proteins","volume":"24","author":"Poznyak","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA118.003176","article-title":"Crystal structures of the human 4-1BB receptor bound to its ligand 4-1BBL reveal covalent receptor dimerization as a potential signaling amplifier","volume":"293","author":"Bitra","year":"2018","journal-title":"J Biol Chem"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e2308132121","DOI":"10.1073\/pnas.2308132121","article-title":"Peptide-based allosteric inhibitor targets TNFR1 conformationally active region and disables receptor-ligand signaling complex","volume":"121","author":"Zeng","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21051778","article-title":"A systematic test of receptor binding kinetics for ligands in tumor necrosis factor superfamily by computational simulations","volume":"21","author":"Su","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.581213","article-title":"Heparan sulfate proteoglycans: key mediators of stem cell function","volume":"8","author":"Ravikumar","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00050.2022","article-title":"Coreceptor functions of cell surface heparan sulfate proteoglycans","volume":"322","author":"Hayashida","year":"2022","journal-title":"Am J Physiol Cell Physiol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cdd.4401647","article-title":"Heparan sulfate proteoglycan binding promotes APRIL-induced tumor cell proliferation","volume":"12","author":"Hendriks","year":"2005","journal-title":"Cell Death Differ"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.615141","article-title":"Receptor oligomerization and its relevance for signaling by receptors of the tumor necrosis factor receptor superfamily","volume":"8","author":"Kucka","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1038\/s41467-021-21563-z","article-title":"West, S.M. et\u00a0al. Structures of mouse and human GITR\u2013GITRL complexes reveal unique TNF superfamily interactions","volume":"12","author":"Wang","year":"2021","journal-title":"Nat Commun"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/cells13060485","article-title":"NF-\u03baB as an inducible regulator of inflammation in the central nervous system","volume":"13","author":"Anilkumar","year":"2024","journal-title":"Cells"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2012.05.009","article-title":"The complexity of the BAFF TNF-family members: implications for autoimmunity","volume":"39","author":"Lahiri","year":"2012","journal-title":"J Autoimmun"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02747","article-title":"Revisiting the concept of targeting NFAT to control T cell immunity and autoimmune diseases","volume":"9","author":"Lee","year":"2018","journal-title":"Front Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12041045","article-title":"Transmembrane activator and CAML interactor (TACI): another potential target for immunotherapy of multiple myeloma","volume":"12","author":"Xu","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B48","doi-asserted-by":"crossref","DOI":"10.1007\/978-0-387-70630-6_3","article-title":"Physiological roles and mechanisms of signaling by TRAF2 and TRAF5","volume-title":"Madame curie bioscience database","author":"Au","year":""},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1186\/1756-9966-33-8","article-title":"The activation of c-Jun NH2-terminal kinase is required for dihydroartemisinin-induced autophagy in pancreatic cancer cells","volume":"33","author":"Jia","year":"2014","journal-title":"J Exp Clin Cancer Res"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1038\/s41467-024-46053-w","article-title":"Distinct transcriptomes and autocrine cytokines underpin maturation and survival of antibody-secreting cells in systemic lupus erythematosus","volume":"15","author":"Chen","year":"2024","journal-title":"Nat Commun"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1117749","article-title":"IgA-producing B cells in lung homeostasis and disease","volume":"14","author":"Bertrand","year":"2023","journal-title":"Front Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2015.02.011","article-title":"A proliferation-inducing ligand sustains the proliferation of human na\u00efve (CD27-) B cells and mediates their differentiation into long-lived plasma cells in vitro via transmembrane activator and calcium modulator and cyclophilin ligand interactor and B-cell mature antigen","volume":"295","author":"Matsuda","year":"2015","journal-title":"Cell Immunol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"e20191167","DOI":"10.1084\/jem.20191167","article-title":"BAFFR controls early memory B cell responses but is dispensable for germinal center function","volume":"218","author":"Lau","year":"2021","journal-title":"J Exp Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3390\/ijms251910845","article-title":"B-cell maturation antigen (BCMA) as a biomarker and potential treatment target in systemic lupus erythematosus","volume":"25","author":"Martin","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B55","doi-asserted-by":"publisher","first-page":"e30330","DOI":"10.7759\/cureus.30330","article-title":"An overview of systemic lupus erythematosus (SLE) pathogenesis, classification, and management","volume":"14","author":"Ameer","year":"2022","journal-title":"Cureus"},{"key":"B56","article-title":"Systemic lupus erythematosus","volume-title":"StatPearls","author":"Justiz Vaillant","year":"2024"},{"key":"B57","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1681\/ASN.2010050515","article-title":"Local renal autoantibody production in lupus nephritis","volume":"22","author":"Espeli","year":"2011","journal-title":"J Am Soc Nephrology: JASN"},{"key":"B58","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s12519-019-00229-3","article-title":"Immunological pathogenesis and treatment of systemic lupus erythematosus","volume":"16","author":"Pan","year":"2020","journal-title":"World J Pediatr"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2023.156411","article-title":"Macrophages derived from LPS-stimulated monocytes from individuals with subclinical atherosclerosis were characterized by increased pro-inflammatory activity","volume":"172","author":"Nikiforov","year":"2023","journal-title":"Cytokine"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12196268","article-title":"B cell tolerance and targeted therapies in SLE","volume":"12","author":"Parodis","year":"2023","journal-title":"J Clin Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2020.102490","article-title":"Are lupus animal models useful for understanding and developing new therapies for human SLE","volume":"112","author":"Moore","year":"2020","journal-title":"J Autoimmun"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25105351","article-title":"Human and murine toll-like receptor-driven disease in systemic lupus erythematosus","volume":"25","author":"von Hofsten","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac528","article-title":"SLE stratification based on BAFF and IFN-I bioactivity for biologics and implications of BAFF produced by glomeruli in lupus nephritis","author":"Itotagawa","year":"2023","journal-title":"Rheumatol (Oxford)"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1177\/0961203315608254","article-title":"Association of BAFF, APRIL serum levels, BAFF-R, TACI and BCMA expression on peripheral B-cell subsets with clinical manifestations in systemic lupus erythematosus","volume":"25","author":"Salazar-Camarena","year":"2016","journal-title":"Lupus"},{"key":"B65","doi-asserted-by":"publisher","first-page":"R167","DOI":"10.1186\/ar2076","article-title":"Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis","volume":"8","author":"Vallerskog","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1305865","article-title":"Comparative analysis of contemporary anti-double stranded DNA antibody assays for systemic lupus erythematosus","volume":"14","author":"Bauer","year":"2023","journal-title":"Front Immunol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13075-022-02794-x","article-title":"Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial","volume":"24","author":"D\u00f6rner","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.12997\/jla.2023.12.3.223","article-title":"Mechanisms of the wnt pathways as a potential target pathway in atherosclerosis","volume":"12","author":"Poznyak","year":"2023","journal-title":"J Lipid Atheroscler"},{"key":"B69","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41467-020-20460-1","article-title":"SLE non-coding genetic risk variant determines the epigenetic dysfunction of an immune cell specific enhancer that controls disease-critical microRNA expression","volume":"12","author":"Hou","year":"2021","journal-title":"Nat Commun"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1257085","article-title":"Serum profiling identifies CCL8, CXCL13, and IL-1RA as markers of active disease in patients with systemic lupus erythematosus","volume":"14","author":"Lindblom","year":"2023","journal-title":"Front Immunol"},{"key":"B71","article-title":"Arthritis","volume-title":"StatPearls","author":"Senthelal","year":"2024"},{"key":"B72","article-title":"Rheumatoid arthritis","volume-title":"StatPearls","author":"Chauhan","year":"2024"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3390\/cells12071072","article-title":"Impaired mitochondrial function in T-lymphocytes as a result of exposure to HIV and ART","volume":"12","author":"Blagov","year":"2023","journal-title":"Cells"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23179833","article-title":"Role of citrullinated collagen in autoimmune arthritis","volume":"23","author":"Myers","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2019.106659","article-title":"Generation of a robust model for inducing autoimmune arthritis in Sprague Dawley rats","volume":"102","author":"De","year":"2020","journal-title":"J Pharmacol Toxicol Methods"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.887460","article-title":"How to model rheumatoid arthritis in animals: from rodents to non-human primates","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Immunol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1093\/discim\/kyac010","article-title":"Bench to bedside: modelling inflammatory arthritis","volume":"2","author":"Chidomere","year":"2022","journal-title":"Discov Immunol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"2606916","DOI":"10.1155\/2022\/2606916","article-title":"Preliminary report: osteoarthritis and rheumatoid arthritis synovial fluid increased osteoclastogenesis in vitro by monocyte differentiation pathway regulating cytokines","author":"Luukkonen","year":"2022","journal-title":"Mediators Inflammation"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.750753","article-title":"B cells in rheumatoid arthritis:Pathogenic mechanisms and treatment prospects","volume":"12","author":"Wu","year":"2021","journal-title":"Front Immunol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.763702","article-title":"Monocytes, macrophages, and their potential niches in synovial joints - therapeutic targets in post-traumatic osteoarthritis","volume":"12","author":"Haubruck","year":"2021","journal-title":"Front Immunol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1164137","article-title":"Effects of synovial macrophages in osteoarthritis","volume":"14","author":"Zhao","year":"2023","journal-title":"Front Immunol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3906\/sag-2011-235","article-title":"Autoimmunity in psoriatic arthritis: pathophysiological and clinical aspects","volume":"51","author":"Emmungil","year":"2021","journal-title":"Turkish J Med Sci"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241411662","article-title":"Inflammatory cytokines in psoriatic arthritis: understanding pathogenesis and implications for treatment","volume":"24","author":"Lee","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B84","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s13075-022-02980-x","article-title":"Multiparametric autoantibody analysis: a new paradigm for the diagnosis of connective tissue diseases","volume":"24","author":"Bizzaro","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1002\/art.22929","article-title":"Rheumatoid arthritis fibroblast-like synoviocytes express BCMA and are stimulated by APRIL","volume":"56","author":"Nagatani","year":"2007","journal-title":"Arthritis Rheumatol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11175207","article-title":"Low serum BAFF concentration is associated with response to TNF inhibitors in seropositive patients with rheumatoid arthritis","volume":"11","author":"Hern\u00e1ndez-Breijo","year":"2022","journal-title":"J Clin Med"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1186\/s41232-016-0015-4","article-title":"BAFF- and APRIL-targeted therapy in systemic autoimmune diseases","volume":"36","author":"Nakayamada","year":"2016","journal-title":"Inflammation Regener"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1002\/art.41184","article-title":"B cell synovitis and clinical phenotypes in rheumatoid arthritis: relationship to disease stages and drug exposure","volume":"72","author":"Rivellese","year":"2020","journal-title":"Arthritis Rheumatol (Hoboken N.J.)"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3390\/cells13090743","article-title":"Clinical phenotypes, serological biomarkers, and synovial features defining seropositive and seronegative rheumatoid arthritis: A literature review","volume":"13","author":"Perera","year":"2024","journal-title":"Cells"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1093348","article-title":"Clinical implications of synovial tissue phenotypes in rheumatoid arthritis","volume":"10","author":"Bykerk","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1172\/JCI25265","article-title":"BLyS and APRIL in rheumatoid arthritis","volume":"115","author":"Seyler","year":"2005","journal-title":"J Clin Invest"},{"key":"B92","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1186\/ar1010","article-title":"Roles of B cells in rheumatoid arthritis","volume":"5","author":"Silverman","year":"2003","journal-title":"Arthritis Res Ther"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.715894","article-title":"Critical role of synovial tissue-resident macrophage and fibroblast subsets in the persistence of joint inflammation","volume":"12","author":"Kemble","year":"2021","journal-title":"Front Immunol"},{"key":"B94","article-title":"Sj\u00f6gren\u2019s syndrome","volume-title":"Autoimmunity: from bench to bedside","author":"Sarmiento-Monroy","year":"2013"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2021.100138","article-title":"Autoantibodies in Sj\u00f6gren\u2019s syndrome and its classification criteria","volume":"5","author":"Veenbergen","year":"2021","journal-title":"J Trans Autoimmun"},{"key":"B96","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s10238-021-00728-6","article-title":"Sj\u00f6gren\u2019s syndrome: a systemic autoimmune disease","volume":"22","author":"Negrini","year":"2022","journal-title":"Clin Exp Med"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.5114\/reum.2018.80711","article-title":"Subgroups of Sj\u00f6gren\u2019s syndrome patients categorised by serological profiles: clinical and immunological characteristics","volume":"56","author":"Kontny","year":"2018","journal-title":"Reumatologia"},{"key":"B98","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.imlet.2023.06.005","article-title":"Targeting plasma cells in systemic autoimmune rheumatic diseases - Promises and pitfalls","volume":"260","author":"Steinmetz","year":"2023","journal-title":"Immunol Lett"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224854","article-title":"Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial","volume":"83","author":"Wu","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B100","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1186\/ar3906","article-title":"B-cell targeted therapeutics in clinical development","author":"Bl\u00fcml","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"27","author":"Lu","year":"2020","journal-title":"J BioMed Sci"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00240","article-title":"New approaches to targeting B cells for myasthenia gravis therapy","volume":"11","author":"Huda","year":"2020","journal-title":"Front Immunol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.885672","article-title":"Immunogenicity of monoclonal antibodies and the potential use of HLA haplotypes to predict vulnerable patients","volume":"13","author":"Mosch","year":"2022","journal-title":"Front Immunol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1172\/JCI126397","article-title":"\u2026 B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Invest"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01697-0","article-title":"BCMA-targeted biologic therapies: the next standard of care in multiple myeloma therapy","volume":"82","author":"Paul","year":"2022","journal-title":"Drugs"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215949","article-title":"BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma","volume":"553","author":"Yang","year":"2023","journal-title":"Cancer Lett"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00721","article-title":"The maintenance of memory plasma cells","volume":"10","author":"Khodadadi","year":"2019","journal-title":"Front Immunol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.14218\/GE.2023.00061","article-title":"Role of mitochondria in the chronification of inflammation: focus on dysfunctional mitophagy and mitochondrial DNA mutations","volume":"22","author":"Orekhov","year":"2023","journal-title":"Gene Expression"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1001074107","article-title":"Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritis","volume":"107","author":"Huang","year":"2010","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.03.034","article-title":"De novo oligoclonal expansions of circulating plasmablasts in active and relapsing IgG4-related disease","volume":"134","author":"Mattoo","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110583","article-title":"Ligand-independent oligomerization of TACI is controlled by the transmembrane domain and regulates proliferation of activated B cells","volume":"38","author":"Smulski","year":"2022","journal-title":"Cell Rep"},{"key":"B112","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/s41467-018-03323-8","article-title":"A loop region of BAFF controls B cell survival and regulates recognition by different inhibitors","volume":"9","author":"Vigolo","year":"2018","journal-title":"Nat Commun"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.577662","article-title":"BAFF 60-mer, and differential BAFF 60-mer dissociating activities in human serum, cord blood and cerebrospinal fluid","volume":"8","author":"Eslami","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae286","article-title":"Disruption of memory B-cell trafficking by belimumab in patients with systemic lupus erythematosus","volume":"63","author":"Arends","year":"2024","journal-title":"Rheumatol (Oxford)"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1002\/art.34400","article-title":"Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus","volume":"64","author":"Stohl","year":"2012","journal-title":"Arthritis Rheumatol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2100623","article-title":"APRIL drives a coordinated but diverse response as a foundation for plasma cell longevity","volume":"209","author":"Stephenson","year":"2022","journal-title":"J Immunol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008188","article-title":"Syndecan-1 and stromal heparan sulfate proteoglycans: key moderators of plasma cell biology and myeloma pathogenesis","volume":"137","author":"Ren","year":"2021","journal-title":"Blood"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1002\/art.30372","article-title":"Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial","volume":"63","author":"van Vollenhoven","year":"2011","journal-title":"Arthritis Rheumatol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1111366","article-title":"Heterogeneity of antibody-secreting cells infiltrating autoimmune tissues","volume":"14","author":"Giovannini","year":"2023","journal-title":"Front Immunol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2022.2072143","article-title":"Belimumab for systemic lupus erythematosus - Focus on lupus nephritis","volume":"18","author":"Pl\u00fc\u00df","year":"2022","journal-title":"Hum Vaccines immunotherapeutics"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00303","article-title":"Belimumab and rituximab in systemic lupus erythematosus: A tale of two B cell-targeting agents","volume":"7","author":"Wise","year":"2020","journal-title":"Front Med"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.3390\/life13071496","article-title":"Current treatment approach, emerging therapies and new horizons in systemic lupus erythematosus","volume":"13","author":"Athanassiou","year":"2023","journal-title":"Life (Basel Switzerland)"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2019.10.005","article-title":"Efficacy of rituximab in difficult-to-manage autoimmune hepatitis: Results from the International Autoimmune Hepatitis Group","volume":"1","author":"Than","year":"2019","journal-title":"JHEP Rep"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15970","article-title":"Rituximab is a safe and effective alternative treatment for patients with autoimmune hepatitis: Results from the ColHai registry","volume":"44","author":"Riveiro-Barciela","year":"2024","journal-title":"Liver Int"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.3138\/canlivj-2020-0009","article-title":"Rituximab-induced autoimmune hepatitis: A case study and literature review","volume":"3","author":"Galiatsatos","year":"2020","journal-title":"Can Liver J"},{"key":"B126","doi-asserted-by":"publisher","first-page":"e0458","DOI":"10.1097\/HC9.0000000000000458","article-title":"Autoimmune hepatitis: Current and future therapies","volume":"8","author":"Reau","year":"2024","journal-title":"Hepatol Commun"},{"key":"B127","doi-asserted-by":"publisher","first-page":"5427","DOI":"10.1182\/blood-2023-180055","article-title":"Ianalumab, a novel anti-B-cell activating factor (BAFF) receptor (BAFF-R) monoclonal antibody (mAb) in development for immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA), has demonstrated a favorable safety profile in Sj\u00f6gren\u2019s syndrome (SjS), systemic lupus erythematosus (SLE) and chronic lymphocytic leukemia (CLL)","volume":"142","author":"Cuker","year":"2023","journal-title":"Blood"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16035","article-title":"Review article: experimental therapies in autoimmune hepatitis","volume":"52","author":"Halliday","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2019.12.025","article-title":"Anti-CD20-mediated B-cell depletion in autoimmune diseases: successes, failures and future perspectives","volume":"97","author":"Crickx","year":"2020","journal-title":"Kidney Int"},{"key":"B130","doi-asserted-by":"publisher","first-page":"e2249947","DOI":"10.1002\/eji.202249947","article-title":"Therapeutic tactics for targeting B lymphocytes in autoimmunity and cancer","volume":"54","author":"Wemlinger","year":"2024","journal-title":"Eur J Immunol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnaa022","article-title":"New therapeutic horizons for graves\u2019 Hyperthyroidism","volume":"41","author":"Lane","year":"2020","journal-title":"Endocr Rev"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-021-01048-z","article-title":"A milestone in multiple sclerosis therapy: monoclonal antibodies against CD20-yet progress continues","volume":"18","author":"Frisch","year":"2021","journal-title":"Neurotherapeutics: J Am Soc Exp Neurother"},{"key":"B133","doi-asserted-by":"publisher","first-page":"rs.3.rs","DOI":"10.21203\/rs.3.rs-3016327\/v1","article-title":"SLE antibody-secreting cells are characterized by enhanced peripheral maturation and survival programs","author":"Chen","year":"2023","journal-title":"Res square"},{"key":"B134","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/cei\/uxac029","article-title":"Mechanisms of induction of regulatory B cells in the tumour microenvironment and their contribution to immunosuppression and pro-tumour responses","volume":"209","author":"Flores-Borja","year":"2022","journal-title":"Clin Exp Immunol"},{"key":"B135","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jaut.2016.06.002","article-title":"A proliferation inducing ligand (APRIL) promotes IL-10 production and regulatory functions of human B cells","volume":"73","author":"Hua","year":"2016","journal-title":"J Autoimmun"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01368","article-title":"APRIL induces a novel subset of igA+ Regulatory B cells that suppress inflammation via expression of IL-10 and PD-L1","volume":"10","author":"Fehres","year":"2019","journal-title":"Front Immunol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.818814","article-title":"Molecular mechanisms driving IL-10- producing B cells functions: STAT3 and c-MAF as underestimated central key regulators","volume":"13","author":"Mich\u00e9e-Cospolite","year":"2022","journal-title":"Front Immunol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110728","article-title":"Human IL-10-producing B cells have diverse states that are induced from multiple B cell subsets","volume":"39","author":"Glass","year":"2022","journal-title":"Cell Rep"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2019.100011","article-title":"Paradoxical role of Breg-inducing cytokines in autoimmune diseases","volume":"2","author":"Mohd Jaya","year":"2019","journal-title":"J Transl Autoimmun"},{"key":"B140","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/intimm\/dxac048","article-title":"Suppressive mechanisms of regulatory B cells in mice and humans","volume":"35","author":"Matsumura","year":"2023","journal-title":"Int Immunol"},{"key":"B141","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1016\/j.jid.2021.01.013","article-title":"Skin-homing regulatory B cells required for suppression of cutaneous inflammation","volume":"141","author":"Aira","year":"2021","journal-title":"J Invest Dermatol"},{"key":"B142","doi-asserted-by":"publisher","first-page":"e0292028","DOI":"10.1371\/journal.pone.0292028","article-title":"Anti-inflammatory role of APRIL by modulating regulatory B cells in antigen-induced arthritis","volume":"19","author":"Carvalho-Santos","year":"2024","journal-title":"PloS One"},{"key":"B143","doi-asserted-by":"publisher","first-page":"e31837","DOI":"10.1371\/journal.pone.0031837","article-title":"Selective APRIL blockade delays systemic lupus erythematosus in mouse","volume":"7","author":"Huard","year":"2012","journal-title":"PloS One"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.060772","article-title":"Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production","volume":"66","author":"Lavie","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"B145","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/ar2125","article-title":"Cells of the synovium in rheumatoid arthritis","volume":"9","author":"Mauri","year":"2007","journal-title":"B Cells Arthritis Res Ther"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.28784","article-title":"Survivin a pivotal antiapoptotic protein in rheumatoid arthritis","volume":"234","author":"Zafari","year":"2019","journal-title":"J Cell Physiol"},{"key":"B147","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1371\/journal.pmed.0060001","article-title":"Ectopic lymphoid structures support ongoing production of class-switched autoantibodies in rheumatoid synovium","volume":"6","author":"Humby","year":"2009","journal-title":"PloS Med"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.850998","article-title":"Role of the CXCL13\/CXCR5 axis in autoimmune diseases","volume":"13","author":"Pan","year":"2022","journal-title":"Front Immunol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1343020","article-title":"Unraveling the complex interplay between anti-tumor immune response and autoimmunity mediated by B cells and autoantibodies in the era of anti-checkpoint monoclonal antibody therapies","volume":"15","author":"Soussan","year":"2024","journal-title":"Front Immunol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.150219","article-title":"A BAFF\/APRIL-dependent TLR3-stimulated pathway enhances the capacity of rheumatoid synovial fibroblasts to induce AID expression and Ig class-switching in B cells","volume":"70","author":"Bombardieri","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12894","article-title":"Urinary B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL): potential biomarkers of active lupus nephritis","volume":"187","author":"Phatak","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103211","article-title":"Macrophages in Lupus Nephritis: Exploring a potential new therapeutic avenue","volume":"21","author":"Kwant","year":"2022","journal-title":"Autoimmun Rev"},{"key":"B153","doi-asserted-by":"publisher","first-page":"954292","DOI":"10.1155\/2016\/7513892","article-title":"The characteristics and significance of locally infiltrating B cells in lupus nephritis and their association with local BAFF expression","volume":"2013","author":"Sun","year":"2013","journal-title":"Int J Rheumatol"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2019.100027","article-title":"Expression of BAFF, APRIL, and cognate receptor genes in lupus nephritis and potential use as urinary biomarkers","volume":"3","author":"Aguirre-Valencia","year":"2019","journal-title":"J Transl Autoimmun"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-021-00605-2","article-title":"Epithelial-immune cell interplay in primary Sj\u00f6gren syndrome salivary gland pathogenesis","volume":"17","author":"Verstappen","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1002\/art.41558","article-title":"Interleukin-7\/interferon axis drives T cell and salivary gland epithelial cell interactions in sj\u00f6gren\u2019s syndrome","volume":"73","author":"Rivi\u00e8re","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes080","article-title":"The expression of APRIL in Sjogren\u2019s syndrome: aberrant expression of APRIL in the salivary gland","volume":"51","author":"Vosters","year":"2012","journal-title":"Rheumatol (Oxford)"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae154","article-title":"Histopathological comparison of Sj\u00f6gren-related features between paired labial and parotid salivary gland biopsies of sicca patients","volume":"63","author":"Nakshbandi","year":"2024","journal-title":"Rheumatol (Oxford)"},{"key":"B159","doi-asserted-by":"publisher","first-page":"47","DOI":"10.5455\/msm.2024.36.47-53","article-title":"Association of anti-ro\/SSA and anti-la\/SSB autoantibodies with pregnancy outcome in the general population","volume":"36","author":"Dragoutsos","year":"2024","journal-title":"Mater Sociomed"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1115548","article-title":"Isolated anti-Ro52 identifies a severe subset of Sj\u00f6gren\u2019s syndrome patients","volume":"14","author":"Lee","year":"2023","journal-title":"Front Immunol"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1111\/j.1601-0825.2011.01885.x","article-title":"TACI-Fc gene therapy improves autoimmune sialadenitis but not salivary gland function in non-obese diabetic mice","volume":"18","author":"Vosters","year":"2012","journal-title":"Oral Dis"},{"key":"B162","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ekir.2022.12.014","article-title":"Randomized phase 2 trial of telitacicept in patients with igA nephropathy with persistent proteinuria","volume":"8","author":"Lv","year":"2022","journal-title":"Kidney Int Rep"},{"key":"B163","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1358\/dot.2022.58.1.3352743","article-title":"Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein, for the treatment of systemic lupus erythematosus","volume":"58","author":"Fan","year":"2022","journal-title":"Drugs Today (Barc)"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae285","article-title":"Efficacy and safety of telitacicept, a BLyS\/APRIL dual inhibitor, in the treatment of IgA nephropathy: a retrospective case-control study","volume":"17","author":"Wang","year":"2024","journal-title":"Clin Kidney J"},{"key":"B165","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1186\/s40001-023-01320-2","article-title":"Role of telitacicept in the treatment of IgA nephropathy","volume":"28","author":"Wu","year":"2023","journal-title":"Eur J Med Res"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00827","article-title":"The TNFSF members APRIL and BAFF and their receptors TACI, BCMA, and BAFFR in oncology, with a special focus in breast cancer","volume":"10","author":"Kampa","year":"2020","journal-title":"Front Oncol"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrep.2023.101451","article-title":"BAFF induces CXCR5 expression during B cell differentiation in bone marrow","volume":"34","author":"Koizumi","year":"2023","journal-title":"Biochem Biophys Rep"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70028-6","article-title":"Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial","volume":"13","author":"Kappos","year":"2014","journal-title":"Lancet Neurol"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14105","article-title":"Failed B cell survival factor trials support the importance of memory B cells in multiple sclerosis","volume":"27","author":"Baker","year":"2020","journal-title":"Eur J Neurol"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2019.01.031","article-title":"A Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy","volume":"96","author":"Myette","year":"2019","journal-title":"Kidney Int"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.5301\/jn.5000218","article-title":"Serum BAFF is elevated in patients with IgA nephropathy and associated with clinical and histopathological features","volume":"26","author":"Xin","year":"2013","journal-title":"J Nephrol"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaa264","article-title":"High levels of gut-homing immunoglobulin A+ B lymphocytes support the pathogenic role of intestinal mucosal hyperresponsiveness in immunoglobulin A nephropathy patients","volume":"36","author":"Sallustio","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"B173","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.1172\/JCI45563","article-title":"Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy","volume":"121","author":"McCarthy","year":"2011","journal-title":"J Clin Invest"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.04.046","article-title":"After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy","volume":"98","author":"Rauen","year":"2020","journal-title":"Kidney Int"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.5368","article-title":"Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with igA nephropathy: the TESTING randomized clinical trial","volume":"327","author":"Lv","year":"2022","journal-title":"JAMA"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.681503","article-title":"S100a9 protects male lupus-prone NZBWF1 mice from disease development","volume":"12","author":"Davison","year":"2021","journal-title":"Front Immunol"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70055","article-title":"A first-in-human, randomized study of the safety, pharmacokinetics and pharmacodynamics of povetacicept, an enhanced dual BAFF\/APRIL antagonist, in healthy adults","volume":"17","author":"Davies","year":"2024","journal-title":"Clin Transl Sci"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207653","article-title":"Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study","volume":"75","author":"Isenberg","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2022.05.017","article-title":"Randomized phase II JANUS study of atacicept in patients with igA nephropathy and persistent proteinuria","volume":"7","author":"Barratt","year":"2022","journal-title":"Kidney Int Rep"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.642929","article-title":"Association of CD40 gene polymorphisms with systemic lupus erythematosus and rheumatoid arthritis in a chinese han population","volume":"12","author":"Huang","year":"2021","journal-title":"Front Immunol"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24606","article-title":"Comparison of responsiveness of british isles lupus assessment group 2004 index, systemic lupus erythematosus disease activity index 2000, and british isles lupus assessment group 2004 systems tally","volume":"74","author":"Yee","year":"2022","journal-title":"Arthritis Care Res"},{"key":"B182","doi-asserted-by":"publisher","first-page":"e000365","DOI":"10.1136\/lupus-2019-000365","article-title":"Scoring systemic lupus erythematosus (SLE) disease activity with simple, rapid outcome measures","volume":"6","author":"Thanou","year":"2019","journal-title":"Lupus Sci Med"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103428","article-title":"What is the best instrument to measure disease activity in SLE? - SLE-DAS vs Easy BILAG","volume":"23","author":"In\u00eas","year":"2024","journal-title":"Autoimmun Rev"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.022491","article-title":"Raised serum APRIL levels in patients with systemic lupus erythematosus","volume":"64","author":"Koyama","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2017.1291343","article-title":"Inhibition of B cell activating factor (BAFF) in the management of systemic lupus erythematosus (SLE)","volume":"13","author":"Stohl","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab827","article-title":"Disparity in peripheral and renal B-cell depletion with rituximab in systemic lupus erythematosus: an opportunity for obinutuzumab","volume":"61","author":"Reddy","year":"2022","journal-title":"Rheumatol (Oxford England)"},{"key":"B187","doi-asserted-by":"publisher","first-page":"e025687","DOI":"10.1136\/bmjopen-2018-025687","article-title":"Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol","volume":"9","author":"Teng","year":"2019","journal-title":"BMJ Open"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-007-9094-y","article-title":"Sequence analysis of TNFRSF13b, encoding TACI, in patients with systemic lupus erythematosus","volume":"27","author":"Salzer","year":"2007","journal-title":"J Clin Immunol"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1590\/1414-431X2023e12972","article-title":"Sialic acid as the potential link between lipid metabolism and inflammation in the pathogenesis of atherosclerosis","volume":"56","author":"Poznyak","year":"2023","journal-title":"Braz J Med Biol Res"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1038\/ejhg.2012.277","article-title":"\u2026 Genes identified in Asian SLE GWASs are also associated with SLE in Caucasian populations","volume":"21","author":"Wang","year":"2013","journal-title":"Eur J Hum genetics: EJHG"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2011.36","article-title":"The human immunoglobulin A Fc receptor Fc\u03b1RI: a multifaceted regulator of mucosal immunity","volume":"4","author":"Bakema","year":"2011","journal-title":"Mucosal Immunol"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.3345\/cep.2020.00633","article-title":"Understanding the genetics of systemic lupus erythematosus using Bayesian statistics and gene network analysis","volume":"64","author":"Nam","year":"2021","journal-title":"Clin Exp Pediatr"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201746934","article-title":"A mouse model of systemic lupus erythematosus responds better to soluble TACI than to soluble BAFFR, correlating with depletion of plasma cells","volume":"47","author":"Haselmayer","year":"2017","journal-title":"Eur J Immunol"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.794251","article-title":"Adenovirus encoding tumor necrosis factor alpha and interleukin 2 induces a tertiary lymphoid structure signature in immune checkpoint inhibitor refractory head and neck cancer","volume":"13","author":"Clubb","year":"2022","journal-title":"Front Immunol"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1111\/imcb.12228","article-title":"TACI expression and plasma cell differentiation are impaired in the absence of functional I\u03baBNS","volume":"97","author":"Khoenkhoen","year":"2019","journal-title":"Immunol Cell Biol"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201646630","article-title":"TACI-dependent APRIL signaling maintains autoreactive B cells in a mouse model of systemic lupus erythematosus","volume":"47","author":"Tran","year":"2017","journal-title":"Eur J Immunol"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2020.101707","article-title":"TACI constrains TH17 pathogenicity and protects against gut inflammation","volume":"23","author":"Tan","year":"2020","journal-title":"iScience"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S493923","article-title":"The latest progress in the application of telitacicept in autoimmune diseases","volume":"18","author":"Liu","year":"2024","journal-title":"Drug Des Devel Ther"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1472292","article-title":"Comparative efficacy and safety of different recommended doses of telitacicept in patients with systemic lupus erythematosus in China: a systematic review and meta-analysis","volume":"15","author":"Gao","year":"2024","journal-title":"Front Immunol"},{"key":"B200","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.rdc.2021.04.006","article-title":"B cells in systemic lupus erythematosus: from disease mechanisms to targeted therapies","volume":"47","author":"Canny","year":"2021","journal-title":"Rheum Dis Clin North Am"},{"key":"B201","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1177\/09612033251332052","article-title":"Efficacy and safety of telitacicept in the treatment of systemic lupus erythematosus: A retrospective real-world study","volume":"34","author":"Zhang","year":"2025","journal-title":"Lupus"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.3389\/fneph.2023.1346769","article-title":"The role of BAFF and APRIL in IgA nephropathy: pathogenic mechanisms and targeted therapies","volume":"3","author":"Cheung","year":"2024","journal-title":"Front Nephrol"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2013.04.003","article-title":"The BAFF\/APRIL system: emerging functions beyond B cell biology and autoimmunity","volume":"24","author":"Vincent","year":"2013","journal-title":"Cytokine Growth Factor Rev"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13691","article-title":"Dysregulation of B lymphocyte development in the SKG mouse model of rheumatoid arthritis","volume":"170","author":"Kim","year":"2023","journal-title":"Immunology"},{"key":"B205","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41582-023-00800-7","article-title":"Bruton tyrosine kinase inhibitors for multiple sclerosis","volume":"19","author":"Kr\u00e4mer","year":"2023","journal-title":"Nat Rev Neurol"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11206139","article-title":"Bruton\u2019s tyrosine kinase inhibitors: the next frontier of B-cell-targeted therapies for cancer, autoimmune disorders, and multiple sclerosis","volume":"11","author":"Garg","year":"2022","journal-title":"J Clin Med"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16213574","article-title":"The immunomodulatory mechanisms of BTK inhibition in CLL and beyond","volume":"16","author":"Jiang","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.662223","article-title":"Bruton\u2019s tyrosine kinase (BTK) inhibitors and autoimmune diseases: making sense of BTK inhibitor specificity profiles and recent clinical trial successes and failures","volume":"12","author":"Ringheim","year":"2021","journal-title":"Front Immunol"},{"key":"B209","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41392-025-02168-0","article-title":"Systemic lupus erythematosus: updated insights on the pathogenesis, diagnosis, prevention and therapeutics","volume":"10","author":"Dai","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S67264","article-title":"Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF\/APRIL targeting agents","volume":"9","author":"Lenert","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1404191","article-title":"Targeting autoimmune mechanisms by precision medicine in Myasthenia Gravis","volume":"15","author":"Cavalcante","year":"2024","journal-title":"Front Immunol"},{"key":"B212","doi-asserted-by":"publisher","first-page":"e2149675","DOI":"10.1002\/eji.202149675","article-title":"Targeting B cells and plasma cells in autoimmune diseases: From established treatments to novel therapeutic approaches","volume":"53","author":"Merino-Vico","year":"2023","journal-title":"Eur J Immunol"},{"key":"B213","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1186\/ar3909","article-title":"Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity","author":"Mei","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1502712","article-title":"CD19 CAR-T cell therapy: a new dawn for autoimmune rheumatic diseases","volume":"15","author":"Rangel-Pel\u00e1ez","year":"2024","journal-title":"Front Immunol"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26030929","article-title":"Advances in targeted therapy for systemic lupus erythematosus: current treatments and novel approaches","volume":"26","author":"Saegusa","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2025.117018","article-title":"B cell-targeted therapies in systemic lupus erythematosus: Current status and perspectives","volume":"3","author":"Chen","year":"2025","journal-title":"Biochem Pharmacol"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.0000000541","article-title":"Long-term results from an open-label extension study of atacicept for the treatment of igA nephropathy","volume":"36","author":"Barratt","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11050991","article-title":"IgG4 antibodies induced by repeated vaccination may generate immune tolerance to the SARS-coV-2 spike protein","volume":"11","author":"Uversky","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00788","article-title":"In the right place, at the right time: spatiotemporal conditions determining plasma cell survival and function","volume":"10","author":"Lindquist","year":"2019","journal-title":"Front Immunol"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2024.103329","article-title":"The emerging role of BLyS\/APRIL in autoimmune diseases: Biological characteristics, functions, and therapeutic potential","volume":"149","author":"Hu","year":"2024","journal-title":"J Autoimmun"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.611795","article-title":"Immunosuppressive mechanisms of regulatory B cells","volume":"12","author":"Catal\u00e1n","year":"2021","journal-title":"Front Immunol"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.3390\/cells13151274","article-title":"Imbalance of B-cell subpopulations in the microenvironment of sarcoidosis or lung cancer","volume":"13","author":"Raniszewska","year":"2024","journal-title":"Cells"},{"key":"B223","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41573-023-00670-0","article-title":"Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems","volume":"22","author":"Baryakova","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00956","article-title":"Role of multivalency and antigenic threshold in generating protective antibody responses","volume":"10","author":"Slifka","year":"2019","journal-title":"Front Immunol"},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13020205","article-title":"Memory cells in infection and autoimmunity: mechanisms, functions, and therapeutic implications","volume":"13","author":"Giri","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.3390\/cells9122627","article-title":"Skin-associated B cells in the pathogenesis of cutaneous autoimmune diseases-implications for therapeutic approaches","volume":"9","author":"Fetter","year":"2020","journal-title":"Cells"},{"key":"B227","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41392-023-01557-7","article-title":"Vaccine adjuvants: mechanisms and platforms","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B228","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa2305635","article-title":"A phase 2 trial of sibeprenlimab in patients with igA nephropathy","volume":"390","author":"Mathur","year":"2024","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1523392\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T05:32:48Z","timestamp":1754026368000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1523392\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":228,"alternative-id":["10.3389\/fimmu.2025.1523392"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1523392","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]},"article-number":"1523392"}}